Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
Status:
Completed
Trial end date:
2016-12-07
Target enrollment:
Participant gender:
Summary
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg)
twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized
formoterol fumarate (20 μg and 40 μg).